Publications

25.11.25

Quantitative Relationship Between Tominersen Concentrations in Cerebrospinal Fluid and Biomarker Changes in Huntington’s Disease Patients

CNSJournalPharmacometricsRare diseasesTrial design and analysis

Br J Clin Pharmacol. 2025 Nov 25. Online ahead of print.

Yamamoto Y, Silber Baumann HE, Björnsson MA, Grimsey P, Hawellek DJ, Anderson K, Leavitt BR, Landwehrmeyer BG, Tabrizi S, McColgan P, Wild EJ, Sanwald Ducray P.

20.11.25

Exposure-response analysis for time-to-event data in the presence of adaptive dosing: efficient approaches and pitfalls

ConferenceMethodologyMIDDTrial design and analysis

CPT Pharmacometrics Syst Pharmacol. 2025 Nov 20. Online ahead of print.

Lavalley-Morelle A, Le Louedec F, Anziano R, Mentré F, Bergstrand M.

18.11.25

Dose Modifications in Exposure-Response Analyses of Oncology Drug Development: Brigimadlin Case Study

ConferenceMethodologyMIDDOncologyPharmacometricsSpecial considerations

ACoP16 (Oct 2025), Poster: M-115

Le Louedec F, Kang J, Sarr C, Neldemo I, Wiens M, Baron K, Lamar M, Pérez-Pitarch A, Schmid U, Sailer R, Bergstrand M, Busse D.

18.11.25

Exposure-Overall Survival Analysis for Quizartinib in Newly Diagnosed Patients with FMS- Like Tyrosine Kinase 3-Internal-Tandem-Duplication-Positive Acute Myeloid Leukemia

ConferenceOncologyPharmacometricsProgram strategies and efficiencies

ACoP16 (Oct 2025), Poster: S-075

Smania G, Glatard A, Vaddady P, Nakayama S, Inoue H, Mezzalana E, Simonsson USH, Abutarif M, Zheng M.

18.11.25

Simplifying the Communication of Covariate Effects from Pharmacometric Models – The Role of Unconditional Covariate Effects

ConferenceMethodologyMIDDPharmacometrics

ACoP16 (Oct 2025), Poster: T-069

Jonsson EN, Jönsson S, Hansson E, Nyberg J.

Below we provide links to posters, white papers and scientific publications by Pharmetheus affiliates in chronological order. Please note that access to some publications may require a subscription.

Featured Publications

Exposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection

The reference corrected VPC (rcVPC) – an informative model diagnostics for assessing underying exposure-response relationships

Assessing Drug–Drug Interaction and Food Effect for BCS Class 2 Compound BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma Antagonist, Bevurogant) Using a Physiology-Based Pharmacokinetics Modeling (PBPK) Approach with Semi-Mechanistic Absorption

Search Publications

Publications 5 of 229

Featured Publications

Exposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection

The reference corrected VPC (rcVPC) – an informative model diagnostics for assessing underying exposure-response relationships

Assessing Drug–Drug Interaction and Food Effect for BCS Class 2 Compound BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma Antagonist, Bevurogant) Using a Physiology-Based Pharmacokinetics Modeling (PBPK) Approach with Semi-Mechanistic Absorption

Search Publications

Publications 5 of 229

Related content

Science and Services

Case studies

Scientific Publication